The post-market hard-to-heal cases treated by the DFU new drug, Fespixon have been accepted for an oral presentation at 2022 CDS

Published Date:2022-12-02

Original Link:https://www.onenessbio.com/en/news_detail188_1.htm

Statement
No	1	Date of announcement	2022/12/02	Time of announcement	20:03:27
Subject	The post-market hard-to-heal cases treated by the DFU new drug, Fespixon have been accepted for an oral presentation at 2022 CDS
To which item it meets	paragraph 12			Date of events	2022/12/04
Date of institutional investor conference:2022/12/04 Time of institutional investor conference:15:40 (TPE time) Location of institutional investor conference:online conference Outline of institutional investor conference: (1)The post-market hard-to-heal cases treated with Fespixon (new drug for diabetic foot ulcers) have been accepted for an oral presentation at 2022 China Forum on Diabetic Foot and Related Diseases, Annual Conference on Diabetic Foot and Peripheral Vascular Disease of CDS. (2)This conference is organized by the Chinese Medical Association, Chinese Diabetes Society (CDS), and West China Hospital of Sichuan University. The members of CDS are about 1,500 physicians, endocrinologists, nutritionists, etc. There are many professional groups established by CDS including diabetic foot, education and management of diabetes, etc. CDS also has a good relationship with the Japan Association for Diabetes Education and Care, the European Association for the Study of Diabetes (EASD), and the American Diabetes Association (ADA). This presentation will increase the global DFU specialists’ understanding of Fespixon’s therapeutic effect. Any other matters that need to be specified:The presentation slides will be made publicly by being uploaded to Market Observation Post System according to the regulation.